Oxford vaccine start-up files for IPO in US - report

Wednesday, 07. April 2021 12:47

Vaccitech, the company that owns the biotechnology on which AstraZeneca has based its coronavirus vaccine, has filed for an initial public offering (IPO) in the United States, the Financial Times reported on Wednesday.

The start-up could set its offering price as early as this month, sources familiar with the matter told the outlet, adding that the prospective investors include the United Kingdom Treasury, Alphabet's investment arm GV, Sequoia Capital China, and Gilead Sciences, Inc.

Last month, the Wall Street Journal reported that Vaccitech was planning to go public later this year, with an expected valuation of $700 million. Recent concerns regarding a possible connection between the AstraZeneca vaccine and rare blood clots may affect the share price, the report concluded.

Related Links: AstraZeneca plc
Breaking the News / MJ